
First Patient Dosed in Fortress Biotech’s Phase 2 Trial of Triplex Vaccination to Prevent CMV Infections in Stem Cell Transplant Recipients
A Groundbreaking Study on CMV Vaccine Effectiveness in HSCT Recipients A recent study published in the New England Journal of Medicine marks a significant milestone in the field of transplant medicine. This is the first randomized, controlled trial to examine a vaccine’s effectiveness in controlling Cytomegalovirus (CMV) in recipients of Hematopoietic Stem Cell Transplantation (HSCT)…